We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Promethera Biosciences Treats First Patients with Promethera® HepaStem

News   May 15, 2012

 
Promethera Biosciences Treats First Patients with Promethera® HepaStem
 
 
 

RELATED ARTICLES

Some Cancer Drugs Don’t Work by Hitting Their Targets

News

Some cancer drug candidates in clinical trials kill cancerous cells through off-target effects instead of by interacting with their intended molecular targets, according to new study findings.

READ MORE

An Intriguing Way to Target Third Most Common Cancer Gene

News

The TERT gene is the third most commonly mutated gene in cancer. Now a study by Nobel Laureate, Thomas Cech, offers an intriguing new way to target TERT over-activation.

READ MORE

Drug That Combats Memory Loss in Alzheimer's Enters Phase II Trials

News

A new drug may protect against memory loss, nerve damage and other symptoms of Alzheimer's disease. The drug called BPN14770 is now in Phase 2 clinical trials in patients with Alzheimer's and Fragile X syndrome.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE